Despite an overall response rate of 57%, this clinical trial was suspended due to safety concerns then closed early due to insufficient activity of the study drug combination.
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators.
Bisphosphonate therapy is associated with renal toxicity.
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system.
Next-generation flow cytometry involves assessments of both plasma cell-surface antigens and immunoglobulin light-chain expression.
Patients with multiple myeloma may want to avoid consumption of foods associated with Listeria.
A putative mechanism of resistance to BCMA-directed CAR-T therapy involves BCMA antigen loss through cleavage of BCMA from the surface of myeloma cells.
The chance of missing a disease-causing variant can be as high as 100% across some groups.
“Among evaluable patients who were transfusion dependent on ruxolitinib, 6 of 14 patients converted to transfusion independence after the addition of CPI-0610.”
